

terminus and/or by up to 6 amino acids from the C-terminus;

    said B chain having the amino acid sequence:

    Pro-Thr-Pro-Glu-Met-Arg-Glu-Lys-Leu-Cys-Gly-His-His-Phe-Val-Arg-Ala-Leu-Val-Arg-Val-Cys-Gly-Gly-Pro-Arg-Trp-Ser-Thr-Glu-Ala (SEQ ID NO:4)

or said amino acid sequence (SEQ ID NO:4) truncated by up to 5 amino acids from the N-terminus and/or by up to 5 amino acids from the C-terminus;

    said A and B chains linked by disulfide bonds between amino acid residue number 11 of SEQ ID NO:3 amino acid number 10 of SEQ ID NO:4.

22. (Reiterated) The method of claim 21, wherein the synthetic relaxin like factor is attached to a detectable label.

23. (Reiterated) The method of claim 21, wherein the synthetic relaxin like factor is chemically synthesized.

24. (Reiterated) The method of claim 21, wherein the synthetic relaxin like factor is recombinantly produced.

Claims 25-28 are canceled.

#### **REMARKS**

Claims 21-24 are pending in this application.

Claims 25-28 have been canceled and claim 21 has been amended to more particularly point out and distinctly claim the invention.

The amendments to claim 21 are directly responsive to the objections and rejections raised by the Examiner and are fully supported within the originally filed application. Specifically, administering relaxin-like factor to decrease collagen synthesis is disclosed at several places in the specification including page 13, lines 7-8. Further, specific support for administering relaxin-like factor to human cells in order to decrease collagen synthesis is provided in examples such as the example 6.6 shown on page 38. No new matter has been added.

Rejection under 35 U.S.C. §112, first paragraph